|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.30 USD | +3.94% |
|
-5.46% | +3.07% |
| 13/01 | Sarepta reconfirms yearly sales floor for Elevidys of $500.0 mln | RE |
| 13/01 | Sector Update: Health Care Stocks Lower in Afternoon Trading | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5d. change | Varia. Jan 1. | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SAREPTA THERAPEUTICS, INC. | Diagnostic & Testing Substances Manufacturers | +3.45% | -5.46% | +3.07% | -81.33% | -75.33% | 224.87Cr |  | |  |
Technical Rankings Surperformance
- Stock Market
- Equities
- SRPT Stock
- Charts Sarepta Therapeutics, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition